高危型HPV-DNA联合液基细胞学检测对宫颈癌筛查的价值

Value of combined application of high risk human papillomavirus DNA detection and thinprep cytologic test for cervical cancer screening

目的 探究高危型人乳头瘤病毒（high-risk human papillomavirus,HR-HPV）DNA检测联合液基薄层细胞学检测（thinprep cytologic test,TCT）对宫颈癌（cervical cancer,CC）筛查的临床价值。方法 选择经TCT检查异常的宫颈病变患者141例,根据TCT检测结果及宫颈活检结果分级,采用表面等离子谐振法（surface plasmon resonance,SPR）检测HR-HPV-DNA。结果 宫颈活检阳性检出率为65.2%（92/141）明显高于TCT阳性检出率39.0%（55/141）（χ2=19.45,P〈0.05）。HR-HPV-DNA阳性检出率为66.0%（93/141）明显高于TCT阳性检出率39.0%（55/141）（χ2=20.53,P〈0.05）。结论 TCT、HR-HPV-DNA和宫颈活检均为CC重要的筛查方法,TCT联合HR-HPV-DNA检测可提高CC的筛查效率。

Objective To evaluate the diagnostic value of thinprep cytologic test （TCT） combined with high-risk human papillomavirus （HR-HPV） DNA for cervical cancer （CC）. Methods 141 cases of patients with abnormal cervical lesions were abnormal examined by TCT and were graded by the results of TCT and cervical biopsy, the HR-HPV-DNA was detected by surface plasmon resonance （SPR）. Results The cervical biopsy positive rate 65.2% （92/141） was significantly higher than the positive rate of TCT 39.0% （55/141） （ x^2=19.45, P 〈 0.05）. The positive rate of HR-HPV-DNA was 66.0% （93/141） was significantly higher than the positive rate of TCT 39.0% （55/141）, =20.53, P 〈 0.05）. Conclusion TCT, HR-HPV-DNAand cervical biopsy are important clinical diagnostic methods for cervical lesions, combine detection of TCT and HR-HPV-DNA can improve the detection rate of cervical lesions.